CIK 0001768446 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Climb Bio, Inc.
Sign in to watch- Ticker
- CLYM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832273741
- Phone
- 1-866-857-2596
- Business address
- 20 WILLIAM STREET, SUITE G50, WELLESLEY HILLS, MA
- Former names
- Eliem Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,366,820
- in 1 filing, $1.4M under 10b5-1 plans
Net −$1,366,820. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-18 | Pimblett Emily SVP, Finance & CAO | Option exercise · Restricted Stock Units 10b5-1 | −5,000 | 20,000 | ||
| 2025-01-13 | Brennan Aoife President and CEO | Grant or award · Stock Option (Right to Buy) | +1,150,000 | 1,150,000 | ||
| 2025-01-13 | Pimblett Emily SVP, Finance and CAO | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-01-13 | Kaplan Brett Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-01-01 | Thomas Stephen Basil Director | Option exercise | +50,188 | 154,095 | ||
| 2025-01-01 | Thomas Stephen Basil Director | Option exercise · Restricted Stock Units | −50,188 | 50,187 | ||
| 2024-12-19 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −1,235 | $2.02 | $2K | 11,329 |
| 2024-12-18 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +5,000 | 12,564 | ||
| 2024-12-18 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Option exercise · Restricted Stock Units 10b5-1 | −5,000 | 25,000 | ||
| 2024-11-11 | WILLIAMS DOUGLAS E Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2024-11-11 | WILLIAMS DOUGLAS E Director | Grant or award · Stock Option (Right to Buy) | +6,291 | 6,291 | ||
| 2024-09-20 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −1,182 | $8.18 | $10K | 7,573 |
| 2024-09-20 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −9 | $8.06 | $73 | 7,564 |
| 2024-09-18 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +5,000 | 8,755 | ||
| 2024-09-18 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Option exercise · Restricted Stock Units 10b5-1 | −5,000 | 30,000 | ||
| 2024-08-26 | Kaplan Brett Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +465,000 | 465,000 | ||
| 2024-08-26 | Kaplan Brett Chief Operating Officer | Grant or award · Restricted Stock Units | +77,500 | 77,500 | ||
| 2024-07-22 | Morisset Valerie EVP, R&D AND CSO | Sale | −39,005 | $8.07 | $315K | 61,317 |
| 2024-07-22 | Morisset Valerie EVP, R&D AND CSO | Sale | −30,000 | $7.98 | $239K | 31,317 |
| 2024-07-19 | Morisset Valerie EVP, R&D AND CSO | Sale | −10,201 | $7.09 | $72K | 150,322 |
Page 4 of 9 · 166 trades